Nilafustin (Anidulafungin)

Anidulafungin blocks the enzyme β‑(1,3)‑D‑glucan synthase, preventing synthesis of β‑(1,3)‑D‑glucan, an essential component of the fungal cell wall. This disruption leads to cell‑wall weakness, osmotic lysis and death of the fungus.

The prescribed dose of Nilafustin is determined by the treating physician based on the specific infection, patient weight, renal and hepatic function, and other clinical factors. Dosing regimens are not standardized in public information.

Safety of anidulafungin in pregnancy and lactation has not been established. The drug should only be used if the potential benefit justifies the potential risk to the fetus or infant, and a healthcare professional should evaluate each case.

To request Nilafustin, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where needed) and import documentation.

Nilafustin (anidulafungin) belongs to the echinocandin class, which targets the fungal cell wall, unlike azoles that inhibit ergosterol synthesis. Echinocandins are generally fungicidal against Candida and have a favorable safety profile, especially in patients with hepatic impairment, but they require intravenous administration.

Nilafustin must be stored refrigerated at 2‑8 °C, protected from light, and should never be frozen or shaken. During transport, a validated cold‑chain system is required to maintain temperature stability until the product is prepared for infusion.

Nilafustin is supplied as an intravenous solution and is administered by slow infusion into a peripheral or central vein under aseptic conditions. The infusion rate and duration are set by the prescribing clinician and nursing staff according to the patient’s clinical status.

Serious risks include severe hypersensitivity reactions such as anaphylaxis, significant liver enzyme elevations indicating hepatotoxicity, acute renal failure, and hematologic abnormalities like neutropenia or thrombocytopenia. Prompt recognition and discontinuation are essential if these events occur.

Nilafustin is contraindicated in patients with known hypersensitivity to anidulafungin or any component of the formulation. Caution is advised for individuals with severe hepatic or renal impairment, and it should be avoided in pregnant or breastfeeding women unless clearly justified by a physician.